PDF(Pubmed)
Abstract：
UNASSIGNED: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpoint blockade (ICB, PD-1 (+/-) CTLA-4 antibodies) is commonly used for metastatic UM, in particular in HLA-A 02:01-negative patients. However, ICB comes at the cost of potentially severe immune-related adverse events (irAE). Thus, the selection of patient groups that are more likely to benefit from ICB is desirable.
UNASSIGNED: In this analysis, 194 patients with metastatic UM undergoing ICB were included. Patients were recruited from German skin cancer sites and the ADOReg registry. To investigate the association of irAE occurrence with treatment response, progression-free survival (PFS), and overall survival (OS) two cohorts were compared: patients without irAE or grade 1/2 irAE (n=137) and patients with grade 3/4 irAE (n=57).
UNASSIGNED: In the entire population, the median OS was 16.4 months, and the median PFS was 2.8 months. Patients with grade 3/4 irAE showed more favorable survival than patients without or grade 1/2 irAE (p=0.0071). IrAE occurred in 44.7% (87/194), and severe irAE in 29.4% (57/194) of patients. Interestingly, irColitis and irHepatitis were significantly associated with longer OS (p=0.0031 and p=0.011, respectively).
UNASSIGNED: This data may indicate an association between irAE and favorable survival outcomes in patients with metastatic UM undergoing ICB treatment and suggests that a reduced tolerance to tumor antigens could be linked to reduced tolerance to self-antigens.
UNASSIGNED: In this analysis, 194 patients with metastatic UM undergoing ICB were included. Patients were recruited from German skin cancer sites and the ADOReg registry. To investigate the association of irAE occurrence with treatment response, progression-free survival (PFS), and overall survival (OS) two cohorts were compared: patients without irAE or grade 1/2 irAE (n=137) and patients with grade 3/4 irAE (n=57).
UNASSIGNED: In the entire population, the median OS was 16.4 months, and the median PFS was 2.8 months. Patients with grade 3/4 irAE showed more favorable survival than patients without or grade 1/2 irAE (p=0.0071). IrAE occurred in 44.7% (87/194), and severe irAE in 29.4% (57/194) of patients. Interestingly, irColitis and irHepatitis were significantly associated with longer OS (p=0.0031 and p=0.011, respectively).
UNASSIGNED: This data may indicate an association between irAE and favorable survival outcomes in patients with metastatic UM undergoing ICB treatment and suggests that a reduced tolerance to tumor antigens could be linked to reduced tolerance to self-antigens.
摘要：
■尽管转移性葡萄膜黑色素瘤（UM）的治疗有了最新进展，在许多病例中,可获得的进一步治疗方案仍然有限,预后仍然较差.除了Tebentafusp,免疫检查点阻断(ICB，PD-1（+/-）CTLA-4抗体）通常用于转移性UM，特别是在HLA-A02:01阴性患者中。然而,ICB是以潜在的严重免疫相关不良事件（irAE）为代价的。因此，选择更有可能受益于ICB的患者组是可取的.
■在此分析中，包括194例接受ICB的转移性UM患者。患者从德国皮肤癌地点和ADOReg注册表招募。为了研究irAE发生与治疗反应的关系，无进展生存期（PFS），和总生存期（OS）两个队列进行了比较：无irAE或1/2级irAE的患者（n=137）和3/4级irAE的患者（n=57）。
■在整个人口中，中位OS为16.4个月,中位PFS为2.8个月.患有3/4级irAE的患者比没有或没有1/2级irAE的患者表现出更有利的生存率（p=0.0071）。IrAE发生率为44.7%(87/194)，29.4%(57/194)的患者出现严重的irAE。有趣的是,结肠炎和肝炎与较长的OS显著相关(分别为p=0.0031和p=0.011)。
■该数据可能表明irAE与接受ICB治疗的转移性UM患者的有利生存结果之间存在关联，并表明对肿瘤抗原的耐受性降低可能与对自身抗原的耐受性降低有关。
■在此分析中，包括194例接受ICB的转移性UM患者。患者从德国皮肤癌地点和ADOReg注册表招募。为了研究irAE发生与治疗反应的关系，无进展生存期（PFS），和总生存期（OS）两个队列进行了比较：无irAE或1/2级irAE的患者（n=137）和3/4级irAE的患者（n=57）。
■在整个人口中，中位OS为16.4个月,中位PFS为2.8个月.患有3/4级irAE的患者比没有或没有1/2级irAE的患者表现出更有利的生存率（p=0.0071）。IrAE发生率为44.7%(87/194)，29.4%(57/194)的患者出现严重的irAE。有趣的是,结肠炎和肝炎与较长的OS显著相关(分别为p=0.0031和p=0.011)。
■该数据可能表明irAE与接受ICB治疗的转移性UM患者的有利生存结果之间存在关联，并表明对肿瘤抗原的耐受性降低可能与对自身抗原的耐受性降低有关。
